Cue Biopharma (CUE) EBITDA Margin (2018 - 2026)
Cue Biopharma's EBITDA Margin came in at -1112.89% for Q2 2026, down 823.92 percentage points from -288.96% a year earlier.
Powered by 
Analysis
Cue Biopharma (CUE) EBITDA Margin (2018 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Cue Biopharma reported EBITDA Margin of -289.38%, up 181.03 percentage points year-over-year; for FY2025, it came in at -93.18%, up 349.40 percentage points from FY2024.
- EBITDA Margin has increased in each of the last three years, with a five-year change of +1301.25 percentage points (FY2020 to FY2025).
- Going back by year, EBITDA Margin was -442.59% in FY2024 (+497.18 pp), -939.76% in FY2023 (+3261.28 pp), -4201.04% in FY2022 (-3916.90 pp) and -284.14% in FY2021 (+1110.30 pp).
- The Q2 2026 figure represents the lowest quarterly EBITDA Margin since Q1 2025.
- Year-over-year, EBITDA Margin increased in four of the last seven quarters, with an average year-over-year change of -276.85 percentage points.
- The fastest year-over-year change in EBITDA Margin over five years came in Q2 2023 (a gain of 48551.00 percentage points), and the weakest in Q2 2022 (a drop of 49154.54 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 39.16% |
| 10 | Cue Biopharma | 121.14 Mn | 30.41 Mn | - | -1,112.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,112.89% |
| Dec 31, 2025 | 11.97% |
| Sep 30, 2025 | -349.28% |
| Jun 30, 2025 | -288.66% |
| Mar 31, 2025 | -2,895.25% |
| Dec 31, 2024 | -604.44% |
| Sep 30, 2024 | -260.94% |
| Jun 30, 2024 | -386.57% |
| Mar 31, 2024 | -731.51% |
| Dec 31, 2023 | -753.38% |
| Sep 30, 2023 | -537.14% |
| Jun 30, 2023 | -967.58% |
| Mar 31, 2023 | -7,140.11% |
| Dec 31, 2022 | -9,856.29% |
| Sep 30, 2022 | -15,913.24% |
| Jun 30, 2022 | -49,484.62% |
| Mar 31, 2022 | -1,393.20% |
| Dec 31, 2021 | -91.87% |
| Sep 30, 2021 | -530.35% |
| Jun 30, 2021 | -364.70% |
API Access
Cue Biopharma EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CUE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "CUE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CUE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();